Global Patent Index - EP 1071459 A4

EP 1071459 A4 20020717 - METHODS TO PROVOKE ANTI-CANCER IMMUNE RESPONSES

Title (en)

METHODS TO PROVOKE ANTI-CANCER IMMUNE RESPONSES

Title (de)

VERFAHREN ZUR ERREGUNG VON IMMUNREAKTIONEN GEGEN KREBS

Title (fr)

METHODES POUR PROVOQUER DES REPONSES IMMUNITAIRES ANTICANCEREUSES

Publication

EP 1071459 A4 20020717 (EN)

Application

EP 99912724 A 19990319

Priority

  • US 9906048 W 19990319
  • US 7893198 P 19980320

Abstract (en)

[origin: WO9947169A1] The present invention provides methods for inducing an antigen-specific immune response. In one aspect, an effective amount of an antigenic peptide binding protein (APBP) and a cytotoxic agent are administered to the subject. In another aspect, an effective amount of a first polynucleotide encoding an antigenic peptide binding protein and a second polynucleotide encoding a cytotoxic agent are administered to the subject. In another aspect, the methods described herein also include administering an effective amount of an antigen presenting cell (APC) recruitment factor, a cytokine or a co-stimulatory molecule. In yet another embodiment, the cytotoxic agent and the antigen presenting cell recruitment factor are encoded by one polynucleotide. In yet another aspect, the invention provides a method of adoptive immunotherapy by administering to a subject a population of educated, antigen-specific immune effector cells, with or without an effective amount of a cytokine and/or a co-stimulator molecule.

IPC 1-7

A61K 39/395; A61K 45/00; A61K 45/05; A01N 37/18; A01N 43/04; A01N 63/00; C12N 5/02; C12N 5/06; C12N 5/08; C07K 1/00; C07K 16/46; C07H 21/04

IPC 8 full level

C12N 15/09 (2006.01); A01N 37/18 (2006.01); A01N 43/04 (2006.01); A61K 35/76 (2006.01); A61K 38/17 (2006.01); A61K 38/45 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); A61P 43/00 (2006.01); C07H 21/04 (2006.01); C07K 16/46 (2006.01); C12N 5/02 (2006.01)

CPC (source: EP US)

A61K 38/1709 (2013.01 - EP); A61K 38/45 (2013.01 - EP); A61K 39/001176 (2018.08 - EP US); A61P 35/00 (2018.01 - EP); A61P 37/04 (2018.01 - EP); A61P 43/00 (2018.01 - EP); A61K 2039/6043 (2013.01 - EP); A61K 2039/605 (2013.01 - EP)

C-Set (source: EP)

  1. A61K 38/1709 + A61K 2300/00
  2. A61K 38/45 + A61K 2300/00

Citation (search report)

  • [X] US 5242813 A 19930907 - PASTAN IRA [US], et al
  • [X] US 5314813 A 19940524 - PETERSON PER A [US], et al
  • [X] DOWELL R I ET AL: "NEW MUSTARD PRODRUGS FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY: ALTERNATIVES TO THE AMIDE LINK", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 39, no. 5, 1996, pages 1100 - 1105, XP002027294, ISSN: 0022-2623
  • [X] YEE C ET AL: "Prospects for adoptive T cell therapy", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 9, no. 5, October 1997 (1997-10-01), pages 702 - 708, XP004313589, ISSN: 0952-7915
  • [X] OSTRAND-ROSENBERG S ET AL: "TUMOR-SPECIFIC IMMUNITY CAN BE ENHANCED BY TRANSFECTION OF TUMOR CELLS WITH SYNGENEIC MHC-CLASS-II GENES OR ALLOGENEIC MHC-CLASS-I GENES", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, no. SUPPL 6, 1991, pages 61 - 68, XP002065931, ISSN: 0020-7136
  • [Y] NICULESCU-DUVAZ I ET AL: "GENE-DIRECTED ENZYME PRODRUG THERAPY", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 9, no. 1, 1 March 1998 (1998-03-01), pages 4 - 22, XP000729231, ISSN: 1043-1802
  • [Y] CHEN S-H ET AL: "COMBINATION GENE THERAPY FOR LIVER METASTASIS OF COLON CARCINOMA INVIVO", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 7, 1995, pages 2577 - 2581, XP000604926, ISSN: 0027-8424
  • [Y] VILE R G ET AL: "SYSTEMIC GENE THERAPY OF MURINE MELANOMA USING TISSUE SPECIFIC EXPRESSION OF THE HSVTK GENE INVOLVES AND IMMUNE COMPONENT", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 23, 1 December 1994 (1994-12-01), pages 6228 - 6234, XP001061699, ISSN: 0008-5472
  • [Y] BUEELER H ET AL: "INDUCTION OF ANTIGEN-SPECIFIC TUMOR IMMUNITY BY GENETIC AND CELLULAR VACCINES AGAINST MAGE: ENHANCED TUMOR PROTECTION BY COEXPRESSION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND B7-1", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 2, no. 5, 1 September 1996 (1996-09-01), pages 545 - 555, XP002035094, ISSN: 1076-1551
  • [Y] LINDAUER M ET AL: "GENE TRANSFER OF COSTIMULATORY MOLECULES INTO A HUMANCOLORECTAL CANCER CELL LINE: REQUIREMENT OF CD54, CD80 AND CLASS II MHC EXPRESSION FOR ENHANCED IMMUNOGENICITY", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 93, no. 3, March 1998 (1998-03-01), pages 390 - 397, XP000876810, ISSN: 0019-2805
  • [Y] YAMAMOTO SHIRO ET AL: "Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice.", CANCER GENE THERAPY, vol. 4, no. 2, 1997, pages 91 - 96, XP001069247, ISSN: 0929-1903
  • [Y] IWADATE YASUO ET AL: "Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus-thymidine kinase gene ganciclovir administration.", ONCOLOGY (BASEL), vol. 54, no. 4, 1997, pages 329 - 334, XP001070213, ISSN: 0030-2414
  • See also references of WO 9947169A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9947169 A1 19990923; AU 3103699 A 19991011; AU 755706 B2 20021219; CA 2322969 A1 19990923; EP 1071459 A1 20010131; EP 1071459 A4 20020717; JP 2002506832 A 20020305

DOCDB simple family (application)

US 9906048 W 19990319; AU 3103699 A 19990319; CA 2322969 A 19990319; EP 99912724 A 19990319; JP 2000536408 A 19990319